On the other hand, the anti-inflammatory clemastine can confer neuroprotection in ALS mice under conditions of either P2X7 protein upregulation (if administered for a limited time during the asymptomatic phase) [42], or downregulation (if administered at the early symptomatic until end stage) [43]. Here, P2RX7 is linked to amyotrophic lateral sclerosis.